TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nausea Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical benefit of imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change with AGS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operation-related mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of positive Sars CoV-2 PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of positive radiological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of Clinical Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: General safety (number of subjects with adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Local skin tolerability (tolerability score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Best response of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HCV RNA viral load reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asystole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response of Target Treated Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Acceptable Symptoms State (PASS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facial nerve injury
Endpoint domain: Adverse events/effects
Primary endpoint: Salivary fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Serum ACE2 Activity Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic evidence of upper aerodigestive tract deformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported QOL as measured by FACT-MM scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in QOL relative to baseline as measured by FACT-MM scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with self-reported symptoms of depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retrobulbar vascular resistance cutpoint change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with undetectable plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Any Improvement From Baseline in Mucosal Wave Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Absolute Change in Voice Handicap Index Score (Decrease of 18 or More Points) From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Percentage Change From Baseline in Voice Handicap Index Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cancer Detection Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recall Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity monitor usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in pain based on a visual analog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Vital Sign Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Changes in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of surgical site wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total limb fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of Depo-subQ in Uniject among DMPA IM family planning clients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Depo-subQ in Uniject among family planning providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: upper airway volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Mosaicism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality value of NICS DLRS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Local Regional Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete adenoma resection rate (CARE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients achieving HbA1c less than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cartilage Volume Loss of the Lateral Compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs), and Discontinuations Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in HHD UEC Score Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABO and Rh distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ABO antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Motor OFF Ldopa UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diffusion MRI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of Antioxidant Response Element
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Satisfactory outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to ventilation via endotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful breastfeeding outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: level of burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinician rating of suicide risk
Endpoint domain: Adverse events/effects
Primary endpoint: Diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Work Schedule
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: subjective prolapse associated symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cytogenetic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGE2 levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C1P levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable Outcome as Determined by the Glasgow Outcome Scale-Extended (GOSE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cardiovascular and all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Cmax comparison of pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sun Protection Habits Index
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Respiratory quotient/fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically Relevant Positive Outcome for Cutaneous Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Patients With a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of CDX-1140
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of selected identified risks of asenapine
Endpoint domain: Adverse events/effects
Primary endpoint: AUC24 of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factors in dermatologic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: C-peptide value at a year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in C-peptide over a year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacokinetics of AZ2066
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of biologically confirmed STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of new HIV and HCV cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of unprotected vaginal and anal sexual acts with both regular and paying partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in cognitive flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: risk of thrombotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: risk of bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in the number of heavy drinking days per month (HDDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total alcohol consumption (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression, global improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ultrasound response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Met the Individual Success Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum eosinophil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 113608 in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 113608 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TOPICOP© score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: User selection ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of procedure and/or product related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Co-infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Effect on Obstructive Sleep Apnea (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score on the Quality of Recovery-40 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distensibility of aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the result of Fugl-Meyer assessment for UE motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in the result of Modified Ashworth scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in the result of Box and blocks test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in the result of Semmes-Weinstein monofilament (SWM) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in the result of Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incidence of abdominal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cycle control parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding pattern indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of delirium free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer evaluation outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in AK Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Biomarker measurement feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disability measured by WHODAS 2.0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Stand-up-and Sit-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity Score 3 or Higher Oral Chronic Graft Versus Host Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripapillar choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAL D frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite outcomes of adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of skin-self examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quantification of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new adipokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: new hepatokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Laser Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in length of break from sitting in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily total protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with >50% improvement on provocative pad weight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of gamma interferon producing T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interference Effect for the G6 CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consultation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of inflammation reactive TNFR2+ regulatory T cells per mL of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent prolapse-anatomic at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent prolapse-anatomic at 7-10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified PTSD Symptom Scale (MPSS-SR) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale for DSM-5 (CAPS-5) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety diagnostic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to extubation after being fit for weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite of death, myocardial infarction, stent thrombosis, stroke or TIMI major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Disease Activity Score in 28 Joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: success rate of HEM-AVERT™ instrument
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence and/or severity of hemorrhoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects Without a Model 4396 Lead Related Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Distal Tip Electrode Voltage Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal Ring Voltage Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum fasting time over-night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in the total score of the CHIP-CE-Parent form domain Achievement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)
Endpoint domain: Mortality/survival
Primary endpoint: Percent of Subjects Receiving 4 Cycles of RIC Without Interruption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Euro Quality of Life (EQ-5D-3L)- Health State Profile Utility Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Work Productivity and Activity Impairment- Specific Health Version: Percent Overall Work Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Participants Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects achieving PASI_50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tissue damage of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra operative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of ethinyl estradiol and norgestimate metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale-17 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of the TCR treatment
Endpoint domain: Adverse events/effects
Primary endpoint: first defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Delta between Rockport Walking Test value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory profile at exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dermal sensitization reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum administered dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity in the amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left atrial ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of time between onset and cessation of migraine symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in the lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total wait time for surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use